US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris

· Acne vulgaris affects an estimated 650 million people worldwide with a significant impact on quality of life, mental well-being, and self-esteem. · AT-004 targets a novel, TNF-α-modulating anti-inflammatory pathway in the skin, with relevance across multiple inflammatory dermatologic conditions. REYKJAVIK, ICELAND – February 11, 2026 – Arctic Therapeutics (ATx) today announced that the first patients have been enrolled in a Phase IIa randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of topical AT-004 in patients with acne vulgaris (AV).

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease

· The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 in patients diagnosed with Alzheimer’s disease · EMA grants Orphan Drug Designation (ODD) to AT-001 for hereditary cystatin C amyloid angiopathy (HCCAA), a rare familial dementia REYKJAVIK, ICELAND – November 3, 2025 – Arctic Therapeutics (ATx), an Iceland-based clinical-stage biopharmaceutical company, today announced key regulatory milestones for its lead investigational therapy, AT-001, which is in development for both rare and common forms of dementia. ATx has initiated a Phase

Arctic Therapeutics research suggests preventative strategy against HCCAA

· N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) · HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is an ultra-rare Icelandic amyloid disease due to a mutation in the CST3 gene encoding for the protease inhibitor, cystatin C. · HCCAA causes cerebral hemorrhages in asymptomatic carriers of the L68Q variant due to amyloid aggregation with precipitation in brain vessels and tissue. · Findings could guide the development of preventative therapies for related CAAs. Reykjavik, Iceland– April 2, 2025 – Icelandic drug discovery

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

· Funding will accelerate the company’s anti-amyloid treatment for rare and common forms of dementia · As well as bringing forward a new class of treatment for inflammatory skin diseases · Sanos Group CEO Jeppe Ragnar Andersen joins the board   REYKJAVIK, ICELAND and PHILADELPHIA, PA – January 22, 2025 – Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of international investors.   The syndicate includes the EIC Fund, Iceland’s

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media